Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Detecting predictive androgen receptor modifications in circulating prostate cancer cells

Open access
Steinestel, Julie, Luedeke, Manuel, Arndt, Annette, Schnoeller, Thomas J., Lennerz, Jochen K., Wurm, Carina, Maier, Christiane, Cronauer, Marcus V., Steinestel, Konrad, Schrader, Andres J. · 2019 · Oncotarget

Abstract

// Julie Steinestel 1,2,* , Manuel Luedeke 1,* , Annette Arndt 3,* , Thomas J. Schnoeller 1 , Jochen K. Lennerz 4 , Carina Wurm 1 , Christiane Maier 1 , Marcus V. Cronauer 1 , Konrad Steinestel 5 and Andres J. Schrader 1,2 1 Clinic of Urology, University Hospital Ulm, Ulm, Germany 2 Clinic of Urology, University Hospital Muenster, Muenster, Germany 3 Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany 4 Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA 5 Gerhard-Domagk Institute of Pathology, University of Muenster, Muenster, Germany * These authors have contributed equally to the work Correspondence to: Julie Steinestel, email: julie@steinestel.com Keywords : castration-resistant prostate cancer, androgen receptor modification, splice variants, circulating tumor cells Received: March 20, 2015 Accepted: April 07, 2015 Epub: April 23, 2015 Published: June 25, 2019 Abstract Molecular modifications of the androgen receptor (AR) can cause resistance to androgen deprivation therapy (ADT) in prostate cancer patients. Since lack of representative tumor samples hinders therapy adjustments according to emerging AR-modifications, we evaluated simultaneous detection of the two most common AR modifications (AR-V7 splice variant and AR point mutations) in circulating tumor cells (CTCs). We devised a single-tube assay to detect AR-V7 splice variants and AR point mutations in CTCs using immunomagnetic cell isolation, followed by quantitative real-time PCR and DNA pyrosequencing. We prospectively investigated 47 patients with PSA progression awaiting therapy switch. Comparison of response to newly administered therapy and CTC-AR-status allowed effect size estimation. Nineteen (51%) of 37 patients with detectable CTCs carried AR-modifications. Seventeen patients carried the AR-V7 splice variant, one harbored a p.T878A point mutation and one harbored both AR-V7 and a p.H875Y mutation. We estimated a positive predictive value for response and non-response to therapy by AR status in CTCs of ~94%. Based on a conservative calculation, we estimated the effect size for molecularly-informed therapy switches for prospective clinical trial planning to ~27%. In summary, the ability to determine key resistance-mediating AR modifications in CTCs has the potential to considerably improve prostate cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3925

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 158

Metadata

Authors
Steinestel, J., Luedeke, M., Arndt, A., Schnoeller, T. J., Lennerz, J. K., Wurm, C., Maier, C., Cronauer, M. V., Steinestel, K., & Schrader, A. J.
Venue
Oncotarget
Published
2015-04-23
Volume
10
Issue
41
Pages
4213-4223
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1925305957
Cited by
158
References
5
FWCI
23.31
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detecting predictive androgen receptor modifications in circulating prostate cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.3925
The paper
Steinestel, J., Luedeke, M., Arndt, A., Schnoeller, T. J., Lennerz, J. K., Wurm, C., Maier, C., Cronauer, M. V., Steinestel, K., & Schrader, A. J. (2019). Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.3925

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.